Glycine antagonist (GV150526) in acute stroke: a multicentre, double-blind placebo-controlled phase II trial.
about
Ion channels as drug targets in central nervous system disordersSignificant variation in mortality and functional outcome after acute ischaemic stroke between Western countries: data from the tinzaparin in acute ischaemic stroke trial (TAIST).Clinical trials for neuroprotective therapies in intracerebral hemorrhage: a new roadmap from bench to bedside.Middle cerebral artery occlusion model in rodents: methods and potential pitfalls.Mechanisms of organ dysfunction in critical illness: report from a Round Table Conference held in Brussels.Stroke in the female: role of biological sex and estrogen.Grey matter and white matter ischemic damage is reduced by the competitive AMPA receptor antagonist, SPD 502.
P2860
Q27004533-0B9D918C-123A-405E-87CF-1154704F9097Q30996759-DFA64590-54F5-49C8-8039-56DB7A690D70Q33357329-1AAA0E41-78E6-4BA4-AC40-F45A8E4ECC55Q34558344-E9D6BA4E-EEA2-4419-9503-E3BE0522B7D8Q34571280-C66B077F-9B7A-492E-9109-308B5366C341Q35757557-1A8D583B-D548-42AF-A5C3-84D922A24965Q44129729-B5107E8F-C06F-4643-87B0-0FFFF0E328E2
P2860
Glycine antagonist (GV150526) in acute stroke: a multicentre, double-blind placebo-controlled phase II trial.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Glycine antagonist (GV150526) ...... ebo-controlled phase II trial.
@ast
Glycine antagonist (GV150526) ...... ebo-controlled phase II trial.
@en
type
label
Glycine antagonist (GV150526) ...... ebo-controlled phase II trial.
@ast
Glycine antagonist (GV150526) ...... ebo-controlled phase II trial.
@en
prefLabel
Glycine antagonist (GV150526) ...... ebo-controlled phase II trial.
@ast
Glycine antagonist (GV150526) ...... ebo-controlled phase II trial.
@en
P2093
P921
P356
P1476
Glycine antagonist (GV150526) ...... ebo-controlled phase II trial.
@en
P2093
E A Sanders
GAIN Phase II European Study Group
J F Lavelle
P356
10.1159/000047607
P577
2001-01-01T00:00:00Z